Your Messages Inbox
Your Article Summary
See Latest ArticlesEconomic analysis of alvimopan in North American Phase III efficacy trials
American Journal of Health-System Pharmacy, 07/28/09
Bell TJ et al. – In a post hoc analysis, alvimopan was associated with significantly faster upper and lower GI recovery after bowel resection and a mean LOS reduction of one day compared with placebo. The mean estimated hospital cost was $879–$977 less for patients who received alvimopan compared with placebo. The base–case and sensitivity analyses suggest that, on average, the use of alvimopan compared with placebo may have a cost–saving effect in the hospital setting.
Related Articles
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: Medicare, Medicaid and Other US Government Payers Perspectives: The ISPOR Drug Cost Task Force Report-Part IV
Value in Health, 10/19/09
Relevance Score: 84%
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: An International Perspective: The ISPOR Drug Cost Task Force Report-Part VI
Value in Health, 10/29/09
Relevance Score: 82%
The possible macroeconomic impact on the UK of an influenza pandemic
Health Economics, 10/29/09
Relevance Score: 80%
A simple cost-effective high performance liquid chromatographic assay of sulphadoxine in whole blood spotted on filter paper for field studies
Malaria Journal, 10/27/09
Relevance Score: 80%
Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance
Clinical Pharmacokinetics, 10/15/09
Relevance Score: 80%
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
FDA Advisory Panel Unanimously Recommends Expanded Indication for Boston Scientifics Heart Failure Devices Based on Landmark MADIT-CRT Trial
Boston Scientific, 03/19/10
First Publication of Data from Pivotal Clinical Trial for Medtronic Deep Brain Stimulation Therapy for Epilepsy Published Today in Epilepsia
Medtronic, 03/19/10
Human genome sciences announces results of randomized phase 2 trial of mapatumumab in non-small cell lung cancer
Human Genome Sciences, 03/18/10
Article Search
Sponsor